TORVA 40

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

ATORVASTATIN AS CALCIUM TRIHYDRATE SALT

Available from:

UNIPHARM LTD, ISRAEL

ATC code:

C10AA05

Pharmaceutical form:

TABLETS

Composition:

ATORVASTATIN AS CALCIUM TRIHYDRATE SALT 40 MG

Administration route:

PER OS

Prescription type:

Required

Manufactured by:

UNIPHARM LTD, ISRAEL

Therapeutic group:

ATORVASTATIN

Therapeutic area:

ATORVASTATIN

Therapeutic indications:

Torva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL- cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Torva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable.Pediatric patients (10-17 years of age) : Torva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >or = 190 mg/dl or 2. LDL-C remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient.Prevention of cardiovascular and/or cerebrovascular event such as MI or stroke: as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor.In patients with clinically evident coronary heart disease Torva is indicated to:Reduce the risk of non-fatal myocardial infarction.Reduce the risk of fatal and non fatal stroke.Reduce the risk for revascularization procedures.Reduce the risk of hospitalization for CHF.Reduce the risk of angina.

Authorization date:

2020-03-08

Patient Information leaflet

ىتح ،بيبطلا ةراشتسإ نودب ءاودلاب
جلاعلا نع فقوتلا زوجي لا
.ةيحصلا كتلاح ىلع نسحت أرط ولو ءاودلا عباط صيخشت بجي !ةمتعلا يف ةيودأ
لوانت زوجي لا .ءاود اهيف لوانتت ةرم لك يف يئاودلا
رادقملا نم دكأتلاو
.كلذ رملأا مزل اذإ ةيبطلا تاراظنلا عض رشتسإ ،ءاودلا لامعتسإ لوح ةيفاضإ
ةلئسأ كيدل ترفوت اذإ
.يلديصلا وأ بيبطلا
ةيبناجلا ضارعلأا )4
ىدل ةيبناج
ً
اضارعأ ببسي دق اڤروت لامعتسإ نإ ،ءاود
لكب امك
نم ،ةيبناجلا ضارعلأا ةمئاق نم شهدنت لا
.نيلمعتسملا ضعب
.اهنم
ً
ايأ يناعت لاأ زئاجلا
:ةريطخ ةيبناج ضارعأ
امب ةريطخ ةيبناج ضارعأ ىلإ اڤروت
لامعتسإ يدؤي نأ نكمي
:كلذ يف للاتعإ( تلاضعلا يف فعضو ةيساسح
،تلاضعلا يف ملاآ
●
يتلا ،لضعلا ككفت كلذ يف امب ،تلاضعلا
يف لكاشم .)يلضع
دق ةردان نايحأ يفو صاخشلأا ضعب ىدل
ةريطخ نوكت دق
.ةافو ىلإ يدؤي دق يذلا ىلكلا يف ررض ىلإ
يدؤت
:اذإ بيبطلا ىلإ
ً
اروف هجوتلا بجي
:كلذ يف امب ،ةريطخ ةيساسح تاملاعب رعشت
تنك
.ةرجنحلا وأ ناسللا ،نيتفشلا ،هجولا
خافتنإ ○
.علبلا يف وأ سفنتلا يف ةبوعص ○
.راود وأ ءامغإ ○
.
ً
ادج عيرس ضبن
○
.دلجلا يف نيديدش ةكح وأ حفط ○
،ةرجنحلا يف ملأ ،ةنوخس كلذ يف امب
ازنإولفنلإاب ةهيبش ضارعأ ●
:لصفملا يف ملأو قاهرإ ،لاعس
ثيح ةيساسحو فعض ،تلاضعلا يف ملاآ نم
يناعت تنك ○
وأ ةنوخسب تقفارت اذإ ةصاخ .حضاو ببس